Kenvue Stock Sinks Ahead of Trump Announcement Tying Autism to Tylenol Use During Pregnancy

Kenvue (KVUE) shares dropped over 7% to a record low following a Trump administration announcement linking pregnant women's use of acetaminophen, the active ingredient in Tylenol, to an increased risk of autism, though the stock later climbed in after-hours trading. The company strongly disputes this claim, citing scientific studies that show no such link and expressing concern over the potential health risks for expecting mothers from such advice.

Analysis

Kenvue Inc. (KVUE) shares experienced significant pressure, falling over 7% to a record intraday low, directly following a Trump administration announcement linking acetaminophen, the active ingredient in the company's flagship Tylenol product, with an increased risk of autism. The statement from President Trump and Health and Human Services Secretary Robert F. Kennedy Jr. creates substantial headline risk and public perception challenges, reflected in the strongly negative sentiment score (-0.8 for KVUE). Kenvue has responded by strongly refuting the claims, citing scientific evidence that shows no link and expressing concern over the health risks posed by the administration's advice. The stock's subsequent climb in after-hours trading suggests some market participants may view the sell-off as an overreaction, though the situation introduces a high degree of uncertainty, blending political risk with potential regulatory and litigation threats to a core consumer healthcare product.

Key Decisions for Investors

• Investors should monitor for any formal regulatory actions or the initiation of class-action lawsuits, as these would represent a material escalation beyond the initial political statement.
• Given the sharp intraday sell-off and subsequent after-hours recovery, traders should anticipate heightened volatility in KVUE, with price movements likely to be driven by news flow and sentiment rather than immediate fundamentals.
• Long-term holders should assess the potential for enduring brand damage to Tylenol and weigh the strength of Kenvue's scientific defense against the political and legal headwinds.